Evidence map›Paper›PMID 41733106›Full record

ArticleMolecular oncology2026

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

Rodrigo Dienstmann, Eduardo García-Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd and 52 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

62 authors.

Rodrigo DienstmannOncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0001-5997-318X
Eduardo García-GaleaOncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Alice O'FarrellDepartment of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Zak KinsellaSchool of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Maxime MeylanCentre de Recherche des Cordeliers, INSERM 1138, Sorbonne Université, Université Paris Cité, France.
Florent PetitprezCentre de Recherche des Cordeliers, INSERM 1138, Sorbonne Université, Université Paris Cité, France.
Ingrid ArijsVIB Centre for Cancer Biology, Leuven, Belgium.
Tom VenkenVIB Centre for Cancer Biology, Leuven, Belgium.
Hari PsDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Adrian LärkerydData Science & AI, The Centre for Immunotherapy of Cancer, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Ian MillerDepartment of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Janick SelvesDepartment of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse, France.
Nadja Meindl-BeinkerDepartment of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany.
Fiorella Ruiz-PaceOncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Elena ÉlezMedical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.
Raquel Comas-NavarroMedical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.
Frank LincolnDepartment of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Dirk FeySystems Biology Ireland, School of Medicine, University College Dublin, Ireland.
Gift NyamundandaDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Aoife NolanSystems Biology Ireland, School of Medicine, University College Dublin, Ireland.
Joern LewinEpigenomics AG, Berlin, Germany.
Raquel Perez-LopezRadiomics Group, Vall d'Hebron Institute of Oncology (VHIO), Spain.
Jonathan BriodyData Science Centre, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Kathleen BennettData Science Centre, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Walter KolchSystems Biology Ireland, School of Medicine, University College Dublin, Ireland.ORCID 0000-0001-5777-5016
David MatallanasSystems Biology Ireland, School of Medicine, University College Dublin, Ireland.
Alexander KelDepartment of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Enrique ArenasPreclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Spain.
Joaquín ArribasPreclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Spain.
Bart GhesquièreMetabolomics Expertise Center, Leuven, Belgium.
Josep TaberneroMedical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.
Julie MeillerouxDepartment of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse, France.
Deborah McNamaraDepartment of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland.
Ray McDermottCancer Trials Ireland, Dublin, Ireland.
Marvin LimDepartment of Medical Oncology, Tallaght University Hospital, Dublin, Ireland.
Mary O'ReillyDepartment of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.
Brian BirdBon Secours Cork Cancer Centre, Bon Secours Hospital Cork, Ireland.
Lisa StackBon Secours Cork Cancer Centre, Bon Secours Hospital Cork, Ireland.
Lucia MoloneyBon Secours Cork Cancer Centre, Bon Secours Hospital Cork, Ireland.
Patrick MorrisBeaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.
Keith EganCancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, Dublin, Ireland.
Maciej MilewskiCancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, Dublin, Ireland.
Lars ScheuerOnkologische Schwerpunktpraxis Speyer, Germany.
Joachim BehringerOnkologische Schwerpunktpraxis Speyer, Germany.
Georg BolzOnkologische Schwerpunktpraxis Speyer, Germany.
Ramon SalazarMedical Oncology Department, Institut Català d'Oncologia, Spain.
Cristina SantosMedical Oncology Department, Institut Català d'Oncologia, Spain.ORCID 0000-0002-9854-5097
Andrea RuizMedical Oncology Department, Institut Català d'Oncologia, Spain.
Orla CaseyCancer Trials Ireland, Dublin, Ireland.
Verena MurphyCancer Trials Ireland, Dublin, Ireland.
Matthias EbertDepartment of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany.
Livio TrusolinoCandiolo Cancer Institute, FPO IRCCS, Torino, Italy.
Diether LambrechtsVIB Centre for Cancer Biology, Leuven, Belgium.
Anguraj SadanandamDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Catherine Sautès-FridmanCentre de Recherche des Cordeliers, INSERM 1138, Sorbonne Université, Université Paris Cité, France.
Jochen PrehnDepartment of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Paolo NuciforoMolecular Oncology Group, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
Jacques FieschiVeracyte SAS, Marseille, France.
Florence MonvilleVeracyte SAS, Marseille, France.
Darran O'ConnorSchool of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Wolf FridmanCentre de Recherche des Cordeliers, INSERM 1138, Sorbonne Université, Université Paris Cité, France.
Annette ByrneDepartment of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Funding

European Union Studies Association
6 · The paper itself

Abstract

To explore the immune microenvironment of RAS-mutated (RASmt) microsatellite stable (MSS) colon cancer (CC), we retrospectively performed whole exome sequencing, RNA sequencing, and robust digital pathology analyses and studied immune markers in a cohort of 161 patients treated with standard-of-care therapies with early stage disease (both fresh frozen and formalin-fixed paraffin-embedded [FFPE] samples) or 121 patients with metastatic setting (primary tumor FFPE samples). Only a small proportion of cases exhibited a highly infiltrated immune microenvironment, with a strong association between Immunoscore

Indexed as

Colonic NeoplasmsMicrosatellite RepeatsMutationras ProteinsAgedFemaleHumansLymphocytes, Tumor-InfiltratingMaleTumor Microenvironmentras Proteinscolorectal cancerimmuno‐markersimmunoscoremicrosatellite stableRAS mutationtumor‐infiltrating lymphocytes

Identifiers

PMID41733106
PMCPMC13352957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.